AG
BMRN icon

AIA Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

AIA Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Sell
3,764
-3,943
-51% -$216K ﹤0.01% 315
2026
Q1 		$435K Sell
7,707
-6,423
-45% -$375K 0.01% 303
2025
Q4 		$840K Buy
14,130
+10,033
+245% +$546K 0.01% 272
2025
Q3 		$222K Buy
4,097
+377
+10% +$21.6K ﹤0.01% 393
2025
Q2 		$204K Buy
3,720
+595
+19% +$35K ﹤0.01% 326
2025
Q1 		$221K Sell
3,125
-580
-16% -$39K 0.01% 309
2024
Q4 		$244K Buy
3,705
+270
+8% +$18.1K 0.01% 280
2024
Q3 		$241K Buy
3,435
+458
+15% +$38.3K 0.01% 281
2024
Q2 		$245K Sell
2,977
-1,099
-27% -$91.5K 0.01% 274
2024
Q1 		$356K Buy
4,076
+266
+7% +$23.8K 0.01% 259
2023
Q4 		$367K Sell
3,810
-563
-13% -$49.8K 0.02% 250
2023
Q3 		$387K Sell
4,373
-370
-8% -$32.9K 0.02% 235
2023
Q2 		$411K Sell
4,743
-4,767
-50% -$449K 0.02% 265
2023
Q1 		$925K Buy
9,510
+5,197
+120% +$539K 0.05% 162
2022
Q4 		$446K Buy
4,313
+2,707
+169% +$254K 0.03% 237
2022
Q3 		$136K Sell
1,606
-1,106
-41% -$98.5K 0.01% 340
2022
Q2 		$225K Buy
+2,712
New +$216K 0.01% 344

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

AIA Group's BMRN Position: Q2 2026 in Review

AIA Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 51% in Q2 2026, selling an estimated $216K and leaving 3,764 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #315.

AIA Group first reported a position in BMRN in Q2 2022 and has held it in 17 quarters since. The position peaked at $925K in Q1 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • AIA Group held 3,764 shares of BioMarin Pharmaceuticals worth $215K as of Q2 2026.
  • AIA Group sold 3,943 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $216K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of AIA Group's portfolio in Q2 2026, its #315 holding.
  • AIA Group first reported a position in BioMarin Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • AIA Group's BioMarin Pharmaceuticals position peaked at $925K in Q1 2023.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on AIA Group's 13F filing for Q2 2026, filed 31 Jul 2026.